Home
Mission
The mission of the Center for Neurodegenerative Disease Research (CNDR) is to promote and conduct multidisciplinary clinical and basic research to increase the understanding of the causes and mechanisms leading to brain dysfunction and degeneration in neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD), Frontotemporal degeneration (FTD), Amyotrophic lateral sclerosis (ALS), Primary lateral sclerosis (PLS), Motor neuron disease (MND), and related disorders that occur increasingly with advancing age. Implicit in the mission of the CNDR are two overarching goals: 1.) Find better ways to cure and treat these disorders, 2. Provide training to the next generation of scientists.
“My vision for CNDR is to create a world with effective interventions to prevent and cure aging-related neurodegenerative diseases.” – Eddie Lee, MD, PhD, Director of CNDR

John Q. Trojanowski, MD, PhD | 1946 - 2022

In loving memory of John Q. Trojanowski, MD, PhD
Latest Research
-
Patterns and Trends of Glucose-Lowering Therapy in Alzheimer's Disease and Related Dementias
Tuesday, May 12, 2026
No abstract
-
Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI
Monday, May 11, 2026
The creation and ongoing development of the myPPMI platform (see Stanley et al in this issue), has enabled the Parkinson's Progression Markers Initiative (PPMI) to expand our research efforts to acquire additional data, engage a large number of participants, and reduce participant burden to enable long-term follow-up. We now review specific virtual and remote studies and sub-studies including Found, PPMI Online, and PPMI Cognitive that PPMI has developed to enhance participant engagement and...
-
Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease
Monday, May 11, 2026
The Parkinson's Progression Markers Initiative (PPMI) has remained at the vanguard of Parkinson's disease (PD) research through evolving recruitment strategies that mirror advances in PD biology. PPMI was initially focused on untreated, early-stage PD. Over time, it has expanded to include genetic cohorts, prodromal participants identified via olfactory testing and risk factor questionnaires targeting people with rapid eye movement (REM) sleep behavior disorder (RBD). Most recently, PPMI has...